Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio President & CEO Chen Schor received a new stock option award covering 55,000 shares of Common Stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.
The grant vests over four years, with 1/48th of the options vesting on each of the next 48 monthly anniversaries of the grant date. A portion of the vesting can accelerate if specific performance milestones are met, as long as Schor maintains a service relationship with Adicet Bio on each vesting date.
Adicet Bio, Inc. reported that Chief Scientific Officer Blake Aftab received a grant of stock options covering 55,000 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.
These options were granted as compensation and are structured to vest over time. One forty-eighth of the options vests on each of the 48 monthly anniversaries of the grant date, with partial acceleration tied to certain performance milestones, as long as Aftab continues his service relationship with the company.
Adicet Bio director Steve Dubin received a new stock option grant covering 4,200 shares of common stock. The option has an exercise price of $8.10 per share and expires on June 20, 2036. It was awarded as compensation rather than through an open-market purchase or sale.
The option will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Dubin continues serving on the board. Following this grant, he holds 4,200 option shares related to this award.
Adicet Bio director Jeffrey Chodakewitz received a new stock option award covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. Following this grant, he holds stock options for 4,200 underlying shares.
According to the terms, the options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant date, as long as he continues serving on Adicet Bio’s board of directors.
Adicet Bio director Michael Grissinger received a new stock option award covering 4,200 shares of Common Stock. The option was granted at an exercise price of $8.10 per share and expires on June 20, 2036. Following this grant, he holds options for 4,200 shares directly.
The award vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as he continues serving on the board. This is a compensation-related grant, not an open‑market purchase or sale.
Adicet Bio, Inc. director Andrew Sinclair received a grant of stock options as part of his board compensation. He was awarded 4,200 stock options to purchase Adicet Bio common stock at an exercise price of $8.10 per share. These options expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders after the grant date, subject to his continued service on the board. Following this award, Sinclair holds 4,200 derivative securities linked to Adicet Bio common stock.
Adicet Bio director Katie Peng reported receiving a grant of stock options covering 4,200 shares of Adicet Bio common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. According to the grant terms, all 4,200 options will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as she continues serving on the board. After this award, she holds 4,200 stock options directly.
Adicet Bio, Inc. director Lloyd Klickstein received a grant of stock options covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service on the board. This is a routine equity compensation award and does not involve any open-market buying or selling of shares.
Adicet Bio, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where three governance proposals were presented for vote. Stockholders elected Class II directors Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger to three-year terms ending at the 2029 annual meeting.
Support was strong for all three nominees, with votes for ranging from 4,596,116 to 5,257,041 and broker non-votes of 1,384,153. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 4,611,540 votes for and 745,537 against.
In addition, stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 6,719,352 votes for and 25,206 against. No other matters were submitted to a vote at the meeting.
Adicet Bio, Inc. filed an amended annual report to update its disclosure on controls and procedures for the year ended December 31, 2025. The company explains that its original Form 10-K omitted required statements about the effectiveness and design of its disclosure controls and procedures.
Management, including the CEO and CFO, evaluated these disclosure controls and concluded they were effective as of December 31, 2025 and are designed to provide reasonable assurance that required information is properly recorded and reported. They also concluded that internal control over financial reporting was effective at the reasonable assurance level as of the same date, based on the COSO framework, without an auditor attestation because Adicet Bio is a non-accelerated filer.
The amendment does not change the company’s financial statements or other disclosures, and it states that the filing is not an admission that the original report contained any material misstatement or omission. As of June 30, 2025, non-affiliate common stock had an aggregate market value of about $50.5 million, and as of May 19, 2026, there were 9,348,236 common shares outstanding.